Oppenheimer reaffirmed their hold rating on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a report released on Thursday, AnalystRatings.com reports.
ALXN has been the subject of several other research reports. Cfra lowered their price objective on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a strong-buy rating for the company in a research report on Wednesday, May 6th. SunTrust Banks lowered their price target on shares of Alexion Pharmaceuticals from $141.00 to $135.00 and set a buy rating for the company in a report on Friday, May 8th. Morgan Stanley upped their price objective on Alexion Pharmaceuticals from $116.00 to $120.00 and gave the stock an equal weight rating in a report on Thursday, May 7th. BMO Capital Markets decreased their price objective on Alexion Pharmaceuticals from $147.00 to $142.00 and set an outperform rating on the stock in a research report on Thursday, May 7th. Finally, BidaskClub downgraded Alexion Pharmaceuticals from a hold rating to a sell rating in a research report on Thursday, July 23rd. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. Alexion Pharmaceuticals presently has a consensus rating of Buy and an average price target of $143.17.
Shares of ALXN opened at $102.49 on Thursday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.82 and a current ratio of 4.79. The company has a market cap of $22.63 billion, a price-to-earnings ratio of 9.36, a PEG ratio of 0.81 and a beta of 1.46. The stock has a fifty day moving average price of $110.49 and a two-hundred day moving average price of $102.94. Alexion Pharmaceuticals has a 52-week low of $72.67 and a 52-week high of $125.52.
A number of hedge funds have recently bought and sold shares of ALXN. BlackRock Inc. grew its position in shares of Alexion Pharmaceuticals by 3.8% in the 1st quarter. BlackRock Inc. now owns 16,510,976 shares of the biopharmaceutical company’s stock valued at $1,482,518,000 after purchasing an additional 597,605 shares during the period. State Street Corp raised its holdings in shares of Alexion Pharmaceuticals by 1.1% in the 1st quarter. State Street Corp now owns 11,082,433 shares of the biopharmaceutical company’s stock valued at $995,092,000 after purchasing an additional 121,299 shares during the period. Clearbridge Investments LLC lifted its stake in Alexion Pharmaceuticals by 2.9% in the 1st quarter. Clearbridge Investments LLC now owns 6,548,218 shares of the biopharmaceutical company’s stock valued at $587,964,000 after purchasing an additional 185,429 shares during the last quarter. Swedbank grew its holdings in Alexion Pharmaceuticals by 8.0% during the first quarter. Swedbank now owns 3,449,801 shares of the biopharmaceutical company’s stock worth $309,758,000 after purchasing an additional 256,871 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Alexion Pharmaceuticals by 2.2% during the first quarter. Geode Capital Management LLC now owns 3,270,353 shares of the biopharmaceutical company’s stock worth $293,039,000 after purchasing an additional 71,609 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Read More: How Buying a Call Option Works
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.